Cambrex Corporation: Business Overview, Financials & Competitive Analysis
Cambrex Corporation scores 7/10 on the AskCyborg Cyborg Score (Solid). Well-positioned CDMO capitalizing on pharmaceutical industry consolidation and domestic supply chain reshoring trends through targeted capacity expansion. Cambrex demonstrates strong market positioning in the CDMO sector with significant capital investments in expansion ($120M in US operations) announced in 2025. The company is executing a clear growth strategy with facility modernization.
What is Cambrex Corporation's industry? Cambrex Corporation (cambrex.com) operates in Pharmaceuticals. AskCyborg classifies Cambrex Corporation under Pharmaceuticals in its company registry.
Cambrex Corporation is a leading provider of contract development and manufacturing services for the pharmaceutical and biotechnology sectors. The company generated annual revenue of $717.6 million in 2026 and serves ...
Cyborg Score thesis
Well-positioned CDMO capitalizing on pharmaceutical industry consolidation and domestic supply chain reshoring trends through...
Read the full analyst-debate transcript →Get the Latest Cambrex Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCambrex Corporation Overview
Pro stress-test →Cambrex Corporation is a leading provider of contract development and manufacturing services for the pharmaceutical and biotechnology sectors. The company generated annual revenue of $717.6 million in 2026 and serves as a critical infrastructure provider supporting drug development and manufacturing across the pharmaceutical industry's full product lifecycle.
Strategic Profile
Pro stress-test →The company is expanding its operational footprint across the United States and Europe to meet rising global demand for high-quality drug development and manufacturing solutions, while enhancing its ability to support customers throughout the entire product lifecycle. Cambrex specializes in complex small molecule development projects and active pharmaceutical ingredient (API) manufacturing.
Competitive Landscape
Pro stress-test →Cambrex competes with firms including Theorem Clinical Research, Recipharm, CordenPharma, Catalent, and Actylis in the CDMO market. The company differentiates through geographic diversification, specialized API capabilities, and integrated drug development services spanning small molecules to peptides.
Industry Context
Cambrex Corporation operates in Pharmaceuticals.
Key facts
Headquarters: East Rutherford, New Jersey · Employees: 1,744 · Revenue: $717.6M